'Hiv rna' presentation slideshows

Hiv rna - PowerPoint PPT Presentation


Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II

Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II

Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II Outline Efficacy Trial Objectives Phase IIb vs Phase III Scientific questions Approaches to the questions HIV infection endpoint Post-infection endpoints Correlates of protective immunity

By Mia_John
(412 views)

Comparison of INSTI vs PI

Comparison of INSTI vs PI

Comparison of INSTI vs PI. FLAMINGO GS-236-0103 ACTG A5257. FLAMINGO Study : DTG QD + 2 NRTI vs DRV/r QD + 2 NRTI. Design. Randomisation* 1 : 1 Open-label. W48. W96. > 18 years ARV-naïve HIV RNA > 1,000 c/mL Any CD4 cell count No primary resistance in RT or protease. N = 243.

By paul
(199 views)

Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology

Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology

CNS pharmacology of antiretroviral drugs and relevant interactions between antiretroviral and CNS drugs. Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology www.hiv-druginteractions.org. Presentation outline.

By waggoner
(277 views)

HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States

HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States

HIV Testing and Prophylaxis to Prevent Mother-to-Child Transmission in the United States. Ma. Teresa C. Ambat, MD Asst Professor TTUHSC-Neonatology 12/2/2008. Introduction.

By marijke
(310 views)

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors. Michael P. Busch representing Blood Systems Research Institute Blood Systems Laboratories University of California, San Francisco BPAC, Sept., 2003.

By clea
(106 views)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI. Antiretroviral (ARV) Therapy in Adults and Children. Similar pathogenesis of HIV infection General virologic and immunologic principals for antiretroviral therapy apply

By xandy
(232 views)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. About this Presentation. These slides were developed using the November 2004 Pediatric Guidelines. The intended audience is clinicians involved in the care of patients with HIV.

By tranquilla
(139 views)

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy . Christopher Behrens, MD Northwest AIDS Education & Training Center University of Washington. CBB/2002. Current Treatment Strategies. DHHS Guidelines regarding when to initiate antiretroviral therapy Adherence Strategic antiretroviral combinations

By fai
(342 views)

Investigational Approaches to Antiretroviral Therapy

Investigational Approaches to Antiretroviral Therapy

Investigational Approaches to Antiretroviral Therapy. Eric S. Daar, M.D. Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles, California.

By saburo
(162 views)

RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes

RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes

RESIST Trials - Grade 3 or 4 AST, ALT or Total Bilirubin: Actions and Outcomes. Use of Lipid Lowering Drugs in RESIST. Percentage. n=108. n=102. n=130. n=79. n=238. n=181. Lipid Lowering Agent Use Among RESIST Participants.

By gaye
(774 views)

HIV & AIDS

HIV & AIDS

HIV & AIDS. Dr Sat Das Associate Professor Lead Consultant Physician, HIV / GUM University Hospitals Coventry & Warwickshire. Topics. What is AIDS and what is HIV Epidemiology of HIV Natural course of HIV Transmission of HIV Treatment of HIV: What is HAART and how it works

By kedma
(373 views)

The PEARLS Study: A Multinational Clinical Trial of HIV Treatment

The PEARLS Study: A Multinational Clinical Trial of HIV Treatment

The PEARLS Study: A Multinational Clinical Trial of HIV Treatment. P rospective E valuation of A ntiretrovirals in R esource L imited S ettings. Worldwide HIV Prevalence (2001). UNAIDS 2001.

By loren
(171 views)

MONOTERAPIA CON DARUNAVIR/RITONAVIR

MONOTERAPIA CON DARUNAVIR/RITONAVIR

MONOTERAPIA CON DARUNAVIR/RITONAVIR. Dr. Jose R Arribas UNIDAD VIH. Conflicto de intereses. He recibido becas de investigación y pagos como conferenciante y asesor de: Janssen Cilag Tibotec Abbott Bristol-Myers

By maximus
(388 views)

Response to combination antiretroviral therapy (cART): variation by age

Response to combination antiretroviral therapy (cART): variation by age

6-12. 13-17. 18-29. 30-39. 40-49. 50-54. 55-59. >60. 6-12. 13-17. 18-29. 30-39. 40-49. 50-54. 55-59. >60. Age group (years). Age group (years). <2. 2-5. 6-12. 13-17. 18-29. 30-39. 40-49. 50-54. 55-59. >60. Age group (years). COHERE.

By jana
(145 views)

Principles of HIV Therapy Simple is Better!

Principles of HIV Therapy Simple is Better!

Principles of HIV Therapy Simple is Better!. Adeel A. Butt, MD Assistant Professor of Medicine and Infectious Diseases University of Pittsburgh Director, VAPHS HIV-ID Clinics Center for Health Equity Research and Promotion. Member of Academic Research Council

By andrew
(99 views)

HIV-1 dynamics Perelson et.al. Science 271:1582 (1996)

HIV-1 dynamics Perelson et.al. Science 271:1582 (1996)

HIV-1 dynamics Perelson et.al. Science 271:1582 (1996). Latently Infected CD4 + lymphocytes. Infected CD4 + lymphocytes. < 1%. > 99%. CD4 + lymphocytes - defective virus. t 1/2 - 1.6 days. t 1/2 - 6 hrs. < 1%. HIV-1. Long lived cell populations. Uninfected, activated

By miyoko
(118 views)

Acute HIV Follow-Up in NC Presented by

Acute HIV Follow-Up in NC Presented by

Acute HIV Follow-Up in NC Presented by . Muhammad “Maxi” Mackalo, DIS. Background of ACUTE HIV. STAT: Screening and Testing for Active Transmission The program has been operating since 2002

By rex
(72 views)

XIX International AIDS Conference 2012 Washington DC, USA, 22-27 July, 2012

XIX International AIDS Conference 2012 Washington DC, USA, 22-27 July, 2012

XIX International AIDS Conference 2012 Washington DC, USA, 22-27 July, 2012 B40: Clinical trials and antiretroviral therapy in children and adolescents. IMPAACT P1066: Raltegravir (RAL) safety and efficacy in HIV infected (+) youth 2 to 18 years of age through week 48.

By trent
(144 views)

Immune Activation, HIV Persistence, and the Cure

Immune Activation, HIV Persistence, and the Cure

Immune Activation, HIV Persistence, and the Cure. Daniel C. Douek , MD, PhD Bethesda, Maryland. What We Talk About When We Talk About Immune Activation. Immune activation occurs early in infection. Virus load. Cytokine. A.R. Stacey et al JV 2009.

By ludwig
(169 views)

At the Heart of Longevity Cardiovascular Health

At the Heart of Longevity Cardiovascular Health

At the Heart of Longevity Cardiovascular Health. A good head and a good heart are always a formidable combination Nelson Mandela Founder of The Elders ( www.theelders.org ) . Peter Reiss Director HIV Monitoring Foundation Professor of Medicine

By dugan
(144 views)

View Hiv rna PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Hiv rna PowerPoint presentations. You can view or download Hiv rna presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.